| Bioactivity | FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2]. |
| Invitro | FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].FSL-1 activates the MAP kinase/NF-κB signaling pathway[2]. Cell Viability Assay[1] Cell Line: |
| Name | FSL-1 TFA |
| Shortening | S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF |
| Formula | C82H141F3N14O20S |
| Molar Mass | 1780.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -80°C |